The generic name for Aimovig is erenumab-aooe [1].
What is erenumab-aooe used for?
Erenumab-aooe is a medication prescribed for the preventive treatment of migraine in adults [1]. It is a calcitonin gene-related peptide (CGRP) receptor antagonist [2].
How does erenumab-aooe work?
Erenumab-aooe works by blocking the activity of CGRP, a molecule that plays a role in migraine pain [2]. By preventing CGRP from binding to its receptor, the medication helps to reduce the frequency of migraine attacks [1][2].
When does erenumab-aooe patent protection end?
Information regarding the patent expiry for erenumab-aooe can be found on DrugPatentWatch.com [3]. Patent expiration dates determine when generic versions of a drug can enter the market [3].
Who manufactures erenumab-aooe?
Aimovig, the brand name for erenumab-aooe, is manufactured by Amgen [1].
What are the potential side effects of erenumab-aooe?
Common side effects of erenumab-aooe include injection site reactions, such as pain, redness, or itching [1]. Some patients may also experience constipation, diarrhea, or muscle spasms [1]. Serious side effects, though rare, can include high blood pressure or allergic reactions [1].
Are there alternatives to erenumab-aooe for migraine prevention?
Yes, there are other preventive treatments available for migraine, including oral medications and other CGRP pathway inhibitors [4]. These alternatives may work differently or have different side effect profiles [4].
How is erenumab-aooe administered?
Erenumab-aooe is administered as a subcutaneous injection [1]. Patients are typically instructed on how to self-inject the medication [1].
What clinical data supports the use of erenumab-aooe?
Clinical trials have demonstrated that erenumab-aooe can significantly reduce the number of monthly migraine days in adults [2]. Studies have also shown improvements in disability and quality of life for patients treated with erenumab-aooe [2].
What is the typical cost of erenumab-aooe?
The cost of erenumab-aooe can vary depending on insurance coverage and pharmacy pricing [5]. Information on pricing and potential assistance programs may be available through the manufacturer or healthcare providers [5].
Sources
1. Aimovig [Package Insert]. Amgen Inc.; 2018.
2. Edvinsson L. CGRP receptor antagonists in migraine treatment. Handb Clin Neurol. 2018;155:267-273. doi:10.1016/B978-0-444-63953-0.00023-1
3. DrugPatentWatch.com
4. Silberstein SD, Loder E, Dayanandan N, Mannix L. Prevalance and impact of chronic migraine. JAMA. 2002;287(24):3247-3251. doi:10.1001/jama.287.24.3247
5. https://www.aimovig.com/cost-and-savings/